ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec
Generics BulletinIndian biosimilars giant Biocon Biologics has struck a deal to supply US not-for-profit organization Civica with insulin aspart drug substance for final manufacturing in the US. Established in 2018, C
Generics BulletinAfter last year winning the “first generic liraglutide approved in a major regulated market,” Biocon has now launched its rival to Victoza and Saxenda in the UK. The GLP-1 peptide will be marketed und
Generics BulletinStelara (ustekinumab) biosimilars are now available from multiple suppliers in the US, after Teva, Sandoz and Biocon Biologics confirmed launches under settlements with originator J&J, while sever